Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial of IRE in Cholangiocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03769753
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : April 16, 2019
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to test any good and bad side effects of surgery using IRE to treat cancer of the bile duct.

Condition or disease Intervention/treatment Phase
Cholangiocarcinoma Device: IRE Device Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This is a prospective, single-center phase I study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Trial Of IRE in Cholangiocarcinoma (TOnIC): Phase I
Actual Study Start Date : December 5, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: intraoperative use of IRE
Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.
Device: IRE Device
For use in ablating soft tissue
Other Name: The NanoKnife IRE device




Primary Outcome Measures :
  1. proportion of patients experiencing a clinically relevant complications [ Time Frame: within 30 days post-IRE ]
    defined as CTCAE (version 5.0) grade 3 or higher complications



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Capable of providing written and oral informed consent in English
  • Locally advanced disease based on preoperative work-up demonstrating that the tumor is unresectable due to portal vein, hepatic artery, and/or bile duct involvement, insufficient hypertrophy response of the future liver remnant after portal vein embolization, or patients not able to tolerate major liver surgery
  • Found to be unresectable intraoperatively based on vascular, biliary, or lymph node (N2) involvement upon exploratory laparotomy
  • Patients will be assessed for chemotherapy prior to treatment with IRE, but given the common problem of recurrent cholangitis, some patients will not be candidates for chemotherapy until after IRE is performed.

Exclusion Criteria:

  • Locally advanced PHC eligible and accepted for liver transplantation evaluation
  • PHC with > 5 cm extension along the common hepatic duct or common bile duct on preoperative imaging or intraoperative ultrasound
  • Metastases to peritoneum, liver or other organs confirmed by percutaneous biopsy, staging laparoscopy or intraoperative frozen section
  • Lymph node metastases beyond N2 stations, confirmed by intraoperative frozen sections or radiographic diagnosis
  • History of cardiac disease:

    • Congestive heart failure (NYHA class >2)
    • Active Coronary Artery Disease (defined as myocardial infarction within 6 months prior to screening)
    • Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers are permitted)
  • Any implanted stimulation device (defined as implantable cardiac device and a pacemaker)
  • Uncontrolled hypertension (blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen)
  • Uncontrolled infections (> grade 2 NCI-CTC, version 3.0)
  • Epilepsy
  • Both narrowing (sclerosis) of the main portal vein and a reduced diameter of either the common hepatic artery, celiac trunk or superior mesenteric artery of >50%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03769753


Contacts
Layout table for location contacts
Contact: T. Peter Kingham, MD 212-639-5260 kinghamt@mskcc.org
Contact: William Jarnagin, MD 212-639-7601

Locations
Layout table for location information
United States, New Jersey
Memoral Sloan Kettering Basking Ridge (Consent and Follow up) Recruiting
Basking Ridge, New Jersey, United States, 07920
Contact: T. Peter Kingham, MD    212-639-5260      
United States, New York
Memorial Sloan Kettering Cancer Center @ Commack (Consent and Follow up) Recruiting
Commack, New York, United States, 11725
Contact: T. Peter Kingham, MD    212-639-5260      
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: T. Peter Kingham, MD    212-639-5260      
Contact: William Jarnagin, MD    212-639-7601      
Principal Investigator: T. Peter Kingham, MD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: T. Peter Kingham, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT03769753     History of Changes
Other Study ID Numbers: 18-489
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Memorial Sloan Kettering Cancer Center:
intraoperative use of IRE
18-489

Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangiocarcinoma
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms